Shifting the Paradigm to Pragmatic Evidence Generation
Integrated evidence generation (IEG) is a framework for generating evidence to support regulatory decision-making in healthcare, automate real-world data collection and grow evergreening data networks that fuel a variety of needs.
› READ THE BLOGPOSTERS
Addressing Gaps in Real-World Data Sources through Automated Extraction of Psychiatric Comorbidities and Medication Side Effects from Clinical Notes
MAY 9, 2024
At ISPOR Annual 2024, Jessica Probst, MPH presented in the AI in HEOR poster tour on Addressing Gaps in Real-World Data Sources through Automated Extraction of Psychiatric Comorbidities and Medication Side Effects from Clinical Notes. This poster was also a Top 5% Finalist for the ISPOR 2024 Research Presentation Awards. View the full poster >>
Real-World Characterization and Management of Alopecia Areata Patients in the U.S.
MAY 16, 2023
View our poster on Real-World Characterization and Management of Alopecia Areata Patients in the U.S. Click to view!
EVENTS
ACCESS Europe
SEP 16, 2024
ACCESS Europe 2024 Date: November 14 – November 16 Location: Barcelona, Spain Booth # 1 For additional information or to schedule a meeting with our experts, contact us at info@om1.com
ISPOR Europe 2024
JUL 18, 2024
ISPOR Europe When: November 17-20 Where: Barcelona, Spain Booth # 1207 OM1 will be at 2024 ISPOR Europe! Our clinical expertise and integrated evidence approach bring together real-world data, AI, and automated, regulatory-enabled platforms to help researchers fill in gaps along the patient journey from bench to bedside. Presentation Title: Harnessing AI to Better Understand[…]
EBOOKS
Real-World Analytics: A Complimentary Suite of Analytic Reports
JUL 15, 2024
A complimentary suite of analytic reports for understanding the reasons behind medication discontinuation, patient outcomes, and prescribing behaviors. Introduction to Real-World Analytics Reasons for Discontinuation Report Comparative Outcomes Report Prescriber Trends Report Meet our Experts View the ebook >>
Analyses & Insights from the OM1 Dermatology Data Network
JUL 15, 2024
Bringing new treatments to market and delivering more precise care is challenging enough. Finding the data to support your programs shouldn’t be. This ebook explores powerful insights, analyses, and use cases from OM1’s Dermatology Network: Dermatologic diseases are complex. Getting valuable insights shouldn’t be. OM1 Dermatology Datasets Psoriasis Psoriatic Arthritis Alopecia Areata Atopic Dermatitis Hidradenitis[…]
VIDEOS
PhenOM: AI Solutions
JUL 16, 2024
PhenOM® is an artificial intelligence (AI)-powered digital phenotyping platform trained using OM1’s repository of linked EMR, claims and other data covering more than 300 million patients. The richness of the source data lets these phenotypes capture many complex facets of the target patients’ journeys. View the video on YouTube >>
OM1 Aspen: Integrated Evidence Generation
JUL 16, 2024
OM1 Aspen leverages our proprietary data sourcing, processing and enrichment technologies, including electronic medical records harmonization, image management, advanced medical text processing and linkage, to deliver a more efficient, cost-effective and scalable approach to research. Tap into our networks or build new ones for automated evidence generation. Harness scientifically robust data from large and diverse[…]
NEWS & ARTICLES
American Academy of Dermatology launches innovative project to improve outcomes for patients with hidradenitis suppurativa
OCT 30, 2024
Read the full press release >> ROSEMONT, Ill. (Oct. 30, 2024) — A new initiative by the American Academy of Dermatology aims to shed light on an often misunderstood and debilitating condition, hidradenitis suppurativa (HS). HS is a chronic progressive condition that can cause painful and boil-like bumps, particularly in a patient’s armpits, thighs, and groin.[…]
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
OCT 28, 2024
Pharmaceutical Executive October 25, 2024 Read the full article >> Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions. On August 9, 2024, the FDA announced that it had[…]
WHITE PAPERS
From Big Data to Measurable Outcomes: OBC
JUL 6, 2017
A heightened focus on value is driving efforts across health care to improve outcomes and reduce costs. For pharmaceutical companies, this focus translates into a shift away from traditional payment models to more outcomes-based, risk sharing agreements. In many ways, these agreements present the opportunity to better align interests across health care’s stakeholders. However, they[…]
Improving Performance under Bundled Care
NOV 5, 2016
The field of medicine is changing rapidly due to two major disruptions – the application of artificial intelligence, such as machine and deep learning and the shift from fee-for-service to value-based payment models. These innovations, which are occurring simultaneously, are fundamentally altering how data are used and how care is provided. To survive in this[…]
WEBINARS
Transform Your Patient Insights with AI-Enhanced Real-World Data
NOV 8, 2024
December 5, 2024 1:00 – 2:00pm ET Register >> In today’s complex healthcare landscape, going beyond traditional data is essential. Join our exclusive webinar to discover how scaling qualitative data from clinical notes, combined with AI, can reveal hidden patterns in patient journeys and treatment drivers, giving you a complete view of your therapy’s impact. Explore[…]
Polaris by OM1: Clinical Trial Recruitment for Faster, Cost-Effective Trials
NOV 8, 2024
Tuesday, November 19, 2024 2:00-3:00PM ET Register >> Clinical trial recruitment remains a major bottleneck for the pharmaceutical industry, with 85% of trials struggling to meet participant targets despite nearly $1.9 billion spent annually. The financial stakes are high, with trial delays, primarily due to patient recruitment costing companies between $600K to $8M per day.[…]